0GZV Stock Chart & Stats
kr215.37
kr0.56(0.30%)
At close: 4:00 PM EST
kr215.37
kr0.56(0.30%)
Day’s Range― - ―
52-Week Rangekr176.30 - kr230.10
Previous CloseN/A
Volume17.36K
Average Volume (3M)108.58K
Market Cap
kr53.81B
Enterprise Valuekr59.66B
Total Cash (Recent Filing)kr4.02B
Total Debt (Recent Filing)kr10.99B
Price to Earnings (P/E)22.8
Beta0.80
Next Earnings
Jul 17, 2026EPS Estimate
2.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.66
Shares Outstanding254,152,370
10 Day Avg. Volume166,450
30 Day Avg. Volume108,580
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)2.03
Price to Sales (P/S)1.70
P/FCF Ratio22.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr260.00Price Target Upside20.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)11.56
Revenue Forecast (FY)kr34.88B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationSustained, high-quality free cash flow (3.3B, +25.9% TTM and ~72% conversion) provides durable internal funding for R&D, service expansion, capex and debt reduction. This strengthens financial flexibility and supports long‑term reinvestment independent of short-term revenue swings.
Recurring Service And Consumables RevenueA business model anchored by services, consumables and aftermarket contracts creates repeatable, defenseable revenue tied to installed base. That revenue mix stabilizes cash flows, raises lifetime customer value and supports margin resilience over multi‑year healthcare spending cycles.
Manageable Leverage And Sizable Equity BaseA moderate debt-to-equity (~0.35) and substantial equity provide capacity for targeted investments, M&A or cyclical cushioning. The balance sheet allows strategic action without immediate liquidity strain, supporting durable operations and multi‑year growth initiatives.
Bears Say
Near-term Revenue WeaknessA TTM revenue decline (-2.5%) signals a pause in top-line momentum that can constrain scale benefits and capex returns. If persistent, weaker organic growth limits service attach expansion and reduces the pace at which improved cash flow can translate into higher long‑term profitability.
Rising Debt Versus Prior Years Reduces FlexibilityAlthough leverage is moderate today, the trend of rising debt versus 2021–2023 narrows strategic optionality. Higher indebtedness increases interest and refinancing risk, slowing potential deleveraging and constraining capital allocation during industry investments or acquisition opportunities.
Profitability Below Historical PeaksMargins have improved but remain below prior peaks, reflecting structural cost or mix pressures. Persistently muted operating and net margins limit return on invested capital and reduce the cushion to absorb pricing pressure or higher input costs over the medium term.
Getinge News
0GZV FAQ
What was Getinge’s price range in the past 12 months?
Getinge lowest share price was kr176.30 and its highest was kr230.10 in the past 12 months.
What is Getinge’s market cap?
Getinge’s market cap is kr53.81B.
When is Getinge’s upcoming earnings report date?
Getinge’s upcoming earnings report date is Jul 17, 2026 which is in 17 days.
How were Getinge’s earnings last quarter?
Getinge released its earnings results on Apr 21, 2026. The company reported kr1.8 earnings per share for the quarter, beating the consensus estimate of kr1.633 by kr0.167.
Is Getinge overvalued?
According to Wall Street analysts Getinge’s price is currently Undervalued.
Does Getinge pay dividends?
Getinge does not currently pay dividends.
What is Getinge’s EPS estimate?
Getinge’s EPS estimate is 2.2.
How many shares outstanding does Getinge have?
Getinge has 254,152,370 shares outstanding.
What happened to Getinge’s price movement after its last earnings report?
Getinge reported an EPS of kr1.8 in its last earnings report, beating expectations of kr1.633. Following the earnings report the stock price went up 0.551%.
Which hedge fund is a major shareholder of Getinge?
Currently, no hedge funds are holding shares in GB:0GZV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Getinge
Getinge AB, founded in 1904 and headquartered in Gothenburg, Sweden, is a prominent global supplier of medical technology solutions. The company's extensive portfolio is designed for critical healthcare environments, including operating rooms, intensive care units, and sterile processing facilities. Its operations are divided into three core segments: Acute Care Therapies, Life Science, and Surgical Workflows. Getinge offers a comprehensive array of specialized equipment and systems. This encompasses advanced solutions for sterile processing and containment, such as sterilizers, washers, isolators, and automated logistic systems. For the life sciences sector, they provide bioreactors, bioprocess control systems, and associated analytics tools. Within acute care and surgical settings, their offerings range from anesthesia machines, specialized monitoring systems, and various disposables, to instruments for cardiac surgery (like beating heart stabilizers), mechanical ventilation products, and extracorporeal life support (ECMO) solutions. Additionally, Getinge provides infrastructure for operating rooms, including lighting, tables, modular systems, and integrated management tools, alongside products for cleaning, disinfection, packaging, and comprehensive sterile supply management. Their product line further extends to diverse catheters (thoracic, endovascular), endoscopic vessel harvesting systems, patient flow and transport solutions, and specialized devices for vascular and cardiothoracic surgery. The company distributes its broad range of products globally through its proprietary sales companies, as well as via agents and distributors, serving markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region.
0GZV Stock 12 Month Forecast
Average Price Target
kr260.00
▲(20.72% Upside)
Technical Analysis
Vitrolife AB
―
CellaVision AB
―
Xvivo Perfusion AB
―
Sectra AB Class B
―
Sedana Medical AB
―
Options Prices
Currently, No data available
---








